Generic Celltrion Project
- Overview
-
The global generic market, which takes up two-thirds of the global pharmaceutical market, is expected to reach a total market worth of 833 billion dollars by 2021. In recognition of this potential for market growth, Celltrion created the Global Chemical Development Division to strengthen our position in the global pharmaceutical market.
- Business Strategy
-
Starting with Temixys, the first incrementally modified drug (IMD) for HIV to be approved by the United States FDA (2018), Celltrion is carrying out a strategy to take the lead in the global generic pharmaceutical market by entering the US and global tender markets, and building its global distribution network.
-
- Secure presence in
the global market -
- Develop IMDs and generic drugs
- Enter the US and global tender markets
- Perform initial clinical trials for new drugs
- Secure presence in
-
- Acquire new portfolios and
boost global sales -
- Carry out global clinical trials for new drugs
- Secure 20 or more generic products in portfolio
- Expand global distribution network
- Acquire new portfolios and
-
- Become a global
pharmaceutical company -
- Globally launch new drugs
- Build a stable sales structure
- Take the lead in the global generic pharmaceutical market
- Become a global